
Subject **Evaluation Advisory Committee Chair Report**

Category **For Information**

Section A: Introduction

- This report provides the Board with an overview of the activities of the Evaluation Advisory Committee (EAC) since the Committee Chair last reported to the Board in December 2025.
- The EAC held a virtual meeting on 18-19 March 2026. The Committee provided formal guidance on the Gavi 5.1 evaluation workplan close-out, the Gavi 6.0 Evaluation Workplan, the evaluation policy revision and approval pathway, and interim ways of working for the evaluation function, as well as collaboration with the Global Fund.
- The Committee was updated on the design of the Measurement, Evaluation and Learning (MEL) 6.0 approach, which introduces a more integrated and adaptive approach to evidence generation, learning, and performance management. The EAC highlighted the importance of maintaining strong evaluation capacity and the critical role of evaluation in identifying blind spots, addressing evidence gaps, and supporting adaptive management, in light of the organisational reforms and evolving funding environment.
- The EAC took note of the closure of key Gavi 5.1 evaluations, including the Joint COVAX and Zero-Dose (ZD) evaluations ([available online](#)), with dissemination and follow-up actions ongoing. These evaluations continue to inform strategic and operational decisions for Gavi 6.0, including country ownership, funding models, and programmatic priorities, building on the strong evidence base established during the Gavi 5.0 period.
- The EAC reviewed progress on the Gavi 6.0 evaluation workplan, including the initiation of new evaluations, notably:
 - Big Catch-Up (BCU) evaluation: inception phase now complete and implementation underway, with emerging findings due in mid-July and draft report in late August.
 - Private Sector Engagement Strategy (PSE) evaluation: inception phase now complete and implementation underway, with a draft report due in July 2026 to inform the Gavi 6.0 PSE strategy development.
- The EAC endorsed refinements to timelines, including approval to shift the African Vaccine Manufacturing Accelerator (AVMA) evaluability assessment to Q3/Q4 2026, pending further Board guidance. The evaluability assessment will help ensure the feasibility of undertaking a useful and credible evaluation as per the Board approved AVMA MEL framework.

- The EAC emphasised the importance of ensuring evaluations are timely, prioritised, and aligned with decision-making needs, particularly given resource constraints and the evolving implementation of Gavi 6.0.
- As part of the evaluation function reform, the EAC considered the approval pathway for revision of the Evaluation Policy, emphasising the need for:
 - early and continuous engagement of the EAC in the process,
 - co-creation of the policy and approval pathway, and
 - greater clarity on the role of the EAC in oversight and advisory functions.
- The EAC also reviewed interim ways of working for 2026, reflecting reduced resourcing and operational changes, including:
 - increased outsourcing of quality assurance for decentralised evaluations,
 - adapted evaluation governance and steering committee arrangements, and
 - more streamlined engagement models with partners and the Secretariat and meeting formats.
- The EAC expressed support for these adaptations while underlining the need to maintain evaluation independence, quality, and proportionality, and to monitor implications over time.
- The EAC reviewed proposed principles and areas for collaboration between Gavi and the Global Fund, encouraging the Secretariat to continue this work and emphasising:
 - the need to build on the [Global Fund Evaluation and Learning Office Audit](#) and Gavi Evaluation Function Review (EFR) findings (see Gavi 6.0 Measurement Framework Targets & Update from the EAC, Doc 14 – Appendix 2), with a clearer definition and specificity of collaboration and respective activities;
 - the application of useful principles for collaboration;
 - the importance of clear value-add and feasibility of activities undertaken; and
 - the Gavi Secretariat to consider the value-add of Joint Evaluations where relevant.
- The EAC Chair report is attached in the form of a presentation as Annex A and the EAC meeting guidance from the meeting is attached as Annex B. Further information can be found in Gavi 6.0 Measurement Framework Targets, Doc 14.

- The next meeting is scheduled for 16-17 September 2026.

Annexes

Annex A: EAC Chair report

Annex B: EAC meeting guidance, 18-19 March 2026

EVALUATION ADVISORY COMMITTEE CHAIR REPORT

BOARD MEETING
James Hargreaves
1-2 July 2026, Geneva, Switzerland

Overarching Issues and Guidance

Gavi 5.1 Evaluation Workplan Close-Out

Guidance on close-out of Gavi 5.0 evaluation workplan and key Gavi 5.1 evaluations: COVAX and zero-dose phase 2

Gavi 6.0 Evaluation Workplan

Guidance on critical touchpoints to streamline processes, reduce transaction costs on relevant teams, timing shift for AVMA Evaluability Assessment and opportunities to strengthen evaluation processes given stakeholders' reduced availability

Evaluation Policy Revision and Interim Ways of Working

Guidance on the approval pathway for policy revision and interim operational ways of working for the evaluation function in 2026

Collaboration with the Global Fund

Principles and areas for evaluation collaboration between Gavi and the Global Fund

Gavi 5.1 Evaluation Workplan close-out and use of evaluation Annex A

Gavi 5.0 evaluation workplan close-Out

Committee updated on close-out of 5.0 workplan and design of MEL 6.0

MEL 6.0 introduces a more integrated and adaptive approach to evidence generation, learning, and performance management

EAC highlighted the critical role of evaluation in identifying blind spots and addressing evidence gaps

EAC noted importance of evaluation in a constrained resource environment

Key Evaluations Closed

Joint COVAX Evaluation Closed — dissemination and follow-up ongoing


Published on Gavi website: see link [here](#)

ZD phase 2 evaluation

Closed — dissemination complete and follow-up actions ongoing

Annual Evaluation Report (2025) published:

See link [here](#)



USE:

The Evaluation of Gavi's contribution to reaching ZD children and missed communities findings contributed evidence to and informed the consolidation of Gavi funding levers into a single grant mechanism for all cash and TA support, reducing fragmentation and improving coherence across grant investments.

The joint COVAX evaluation phase 2 findings – specifically, that future pandemic response mechanisms should adopt a multilateral approach to ensuring equitable access to vaccines – continue to inform the operationalisation of the interim Medical Countermeasures Net (i-MCMnet) and the recently adopted WHO Pandemic Agreement.

Gavi 6.0 Evaluation Workplan

In progress

Big Catch Up (BCU) Evaluation

Inception phase complete
Implementation underway
Final report expected in early Q4

In progress

Private Sector Engagement (PSE) Strategy

Inception phase complete
Implementation underway
Draft report due July 2026 — to inform Gavi 6.0 PSE strategy

AVMA Evaluability Assessment

Timeline shifted to Q3/Q4 2026, pending further governance guidance — endorsed by the EAC

Grant Management Reform and Malaria evaluations: scoping of learning questions and planning for the Evaluability Assessments underway

The EAC endorsed the prioritisation of evaluation touchpoints as indicated to streamline the process, including enhancing country engagement as appropriate to the evaluation purpose/scope and considering efficient ways to include partners at specific touchpoints.

EAC emphasised the importance of follow up of evaluation management response actions with Alliance Partners. Support including language that strengthens partner engagement in evaluations within grant agreements.

EAC advised the Secretariat to seek opportunities in the new working environment to strengthen evaluation, for example drawing on a broader range of evaluation forms.

Gavi 6.0 Costed Evaluation Workplan

	Evaluations	Proposed year evaluation is delivered (& key use case)	Budget
A Continued programmes from 5.1	1. Vaccine Delivery Platforms: Malaria 2. Big Catch-Up 3. Gavi 5.0's board-approved Private Sector and Innovation strategy	2027 (6.0 course-correction & 7.0 design) 2026 (6.0 course-correction & 7.0 design) 2026 (6.0 course-correction & 7.0 design)	500K US\$399.056 US\$345.090
B Programmatic shifts in 6.0	5. Approach to Fragile and Humanitarian Settings 6.0	2029 (7.0 operationalisation)	0.5-1m
C GMR: shifts to funding model and grant management processes	. Gavi 6.0 shifts to: a) <u>funding model</u> (country vaccine budgets, VPOP, campaigns, ELTRACO, HSS policy, MDB multiplier, domestic financing, partnership approach inc. collaboration under Lusaka Agenda); and b) <u>grant management processes</u> (grant cycle alignment, simplification e.g. single application, differentiated approach to grant design,) (Two phases)	Phase 1: 2027 (Mid-Term Review, 7.0 design) Phase 2: 2029 (7.0 operationalisation)	2-3.5m
D AVMA	7. Evaluability Assessment of the African Vaccine Manufacturing Accelerator (AVMA)	2026 (AVMA MEL Framework and endline evaluation)	100k
← EVALUABILITY (300K) →			

Evaluation policy revision and interim ways of working ^{Annex A}

Evaluation Policy revision

EAC approval pathway requirements:

- Early and continuous EAC engagement throughout the process
- Co-creation of both the policy and the approval pathway
- Greater clarity on EAC's oversight/advisory role

Interim ways of working (WOW) 2026

Adaptations reflecting resource constraints:

- Increased outsourcing of quality assurance
- Adapted steering committee arrangements
- More streamlined engagement models and meeting formats

EAC supports these adaptations while underlining the need to maintain evaluation independence, quality, and is supportive of ways of working (WoW) shifts proposed, but notes that they represent a meaningful shift in WOW and to keep under review.

Gavi–Global Fund Collaboration

EAC Guidance on Proposed Collaboration Principles

Build on existing findings

The EAC supported joint learning on Global Fund ELO Audit and Gavi Evaluation Function Review (EFR) findings and advised to define collaboration with greater clarity and specificity

Apply useful principles

Ensure collaboration is guided by clear, agreed principles relevant to both organisations' evaluation mandates

Clear value add

Activities must demonstrate clear value-add and feasibility and avoid overlap or duplication of effort

Joint evaluations

Consider the value-add of Joint Evaluations where relevant, as opportunities mature

Completion of the Gavi-Global Fund Task force assessment of evaluation functions was noted and the EAC supports continued ongoing collaboration and shared learning. *Evaluation-specific collaboration is not currently prioritised — Gavi may proceed with its own policy and process reforms while exploring opportunities as they mature.*

Thank you

Progress update – decentralised evaluations

Annex A

Decentralised Evaluation	Team	Timeline
Development, Implementation, Monitoring and Evaluation of a National and/or Subnational Advocacy Strategy for Increased PHC and Immunisation Financing	IF&S	2022–2026
Design, Implementation, Monitoring, Evaluation and Learning of Country Specific DSI (Conditional Cash or Non-Cash Transfers) for Increasing Demand for Vaccinations, Increasing Coverage and Reducing the Number of ZD Children	IF&S	2023–2026
DHI Roadmap Assessments (costed DHI roadmap studies)	HSIS	2023–2026
Evaluation of Gavi's DHI Strategy	HSIS	2023–2026
Evaluation of the Niger Direct Financing Facility	IF&S	2023–2026
Evaluation of the Djibouti Direct Facility Financing (DFF) and Performance-Based Financing (PBF)	IF&S	2023–2026
Evaluation of the Clinton Health Access Initiative (CHAI) Collaborative Learning Strategic Focus Area (SFA)	IF&S	2024–2026
Afghanistan Unconditional Cash Transfers Plus Programme Evaluation	IF&S	2024–2026
Gender Evaluation	HSIS	2026
Evaluation of HFSE-CCEOP Learning Agenda	HSIS	2025-2026
Demand Process Evaluation	HSIS	2026

Note: As per last update from Gavi teams, Jan 2026. For more info: Annual Evaluation Report 2025

Evaluation Advisory Committee GUIDANCE

EVALUATION ADVISORY COMMITTEE MEETING
March 18-19 2026, Geneva, Switzerland

Item 3 – Gavi 5.1 close-out and 6.0 Evaluation Workplan Update

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Approved shift to the timing of African Vaccine Manufacturing Accelerator (AVMA) Evaluability Assessment and proposal for revision in Q3/Q4 2026 after Q2 Gavi Governance guidance and decisions.
- Endorses the prioritisation of evaluation touchpoints as indicated, including enhancing country engagement as appropriate to the evaluation purpose/scope and considering more efficient ways to include partners at those specific touchpoints.
- Recommends that inclusion of follow up to implementation of evaluation management response is included as a key touchpoint for engagement with Secretariat/Partners.
- Support including language that strengthens partner engagement in evaluations within grant agreements.
- Encourage Measurement Evaluation and Learning (MEL) Department to also seek opportunities in the new working environment to strengthen evaluation, for example drawing on a broader range of evaluation forms, and on Secretariat data consolidation efforts.

Item 4 – Policy Revision Update

The Gavi Alliance Evaluation Advisory Committee (EAC) provided the following formal guidance:

- Suggests updating the proposed pathway for approving the proposed Evaluation Policy in 2026 to include regular and early engagement on co-creation of the way forward, with both the EAC Focal Points and the broader EAC.
- Suggests engagement early in the revision of the revised Evaluation Policy.

Item 5 – 2026 Ways of Working

The Gavi Alliance Evaluation Advisory Committee (EAC) provided the following formal guidance:

- Suggests updating Quality Assurance (QA) cost analysis and sharing with EAC, informed by, and based on, rates from the End-to-End Measurement Evaluation and Learning Request for Proposals.
- Confirms alignment on the EAC taking a holistic look at issues emerging from across the range of External Quality Assurance (EQA).
- Suggests the Evaluation Unit should consider how best to use QA tools in relation to different range of evaluations in the Work Plan.
- Takes note of the potential issue of independence in Evaluation Steering Committees and reaffirms the role of EAC members in safeguarding independence, using agreed pathways, including early identification of if, and when, additional pathways are needed.
- Is supportive of ways of working (WoW) shifts proposed, but notes that they represent a meaningful shift in WOW and to keep under review.

Item 6 – UPDATE ON The Global Fund and Gavi Collaboration

The Gavi Alliance Evaluation Advisory Committee (EAC) provided the following formal guidance:

- Encourages the Secretariat to continue this work, building on the Global Fund Evaluation and Learning Office Audit and Gavi Evaluation Function Review (EFR) findings, with a clearer definition and specificity of collaboration and respective activities; application of useful principles; clear identification of value-add activities; and further consideration of the implications for evaluation quality, and to bring back focused updates as collaboration options mature.
- Encourages the Gavi Secretariat to consider the value-add of Joint Evaluations where relevant.

Thank you